Sana Louise Johnson-Quijada MD

Transcription

1 Sana Louise Johnson-Quijada MD Viking Clinical Research Center Education La Sierra University, Riverside, CA BS Biology 1994 Loma Linda University, Loma Linda, CA MD Degree 1998 Licenseure/Certifications Massachusetts Board of Registration in Medicine 2001 California Medical Board 1998 HAM-A, HAM-D, MADRS, Jung Mania Scale, LSAS, BPRS, PANSS, CGI, SANS, QOL, SIMPSON-ANGUS, AIMS, SCID-I and SCID-II Internships and Residences Loma Linda University 2001 Department of Psychiatry Harvard South Shore 2002 Chief Resident in Psychiatry Medical Practice / Employment Investigator 2004-Present Temecula, CA Temecula Valley Psychiatric Medical Group July 2004-Present Private Practice Temecula, CA Sana Johnson-Quijada, M.D., Inc. Sept 2002-July 2004 Private Practice Redlands, CA Service Director, Staff Psychiatrist Sept 2002-Present Canyon Ridge Hospital Chino, CA 91710

2 Staff Psychiatrist Sept Jan 2003 California Rehabilitation Center Norco, CA Faulkner Hospital Boston, MA Mt. Auburn Hospital Cambridge, MA Newton-Wellesley Hospital Newton, MA Cambridge Psychiatric Services Cambridge, MA House- Staff Psychiatrist Jul 2001-Aug 2002 Harvard South Shore Brockton, MA Staff Psychiatrist Mar 2001-Jun 2001 Inland AIDS Clinic San Bernardino, CA Staff Psychiatrist Mar 2001-Jun 2001 Kaiser Permanente Fontana, CA Staff Psychiatrist Dec 2000-Mar 2001 Temecula Psychiatric Services Temecula, CA House Staff Psychiatrist Sept 1998-Jun 2001 Loma Linda University Loma Linda, CA 92354

3 Hospital Appointments Canyon Ridge Hospital 2002-Present Chino, CA California Rehabilitation Center Norco, CA Faulkner Hospital 2002 Boston, MA Mt. Auburn Hospital 2002 Cambridge, MA Newton-Wellesley Hospital 2002 Newton, MA Cambridge Psychiatric Services 2002 Cambridge, MA Harvard South Shore Brockton, MA Inland AIDS Clinic 2001 San Bernardino, CA Kaiser Permanente 2001 Fontana, CA Temecula Psychiatric Services 2000 Temecula, CA Professional Societies American Psychiatric Association 1997 Invited Presentations Sleep Disorders 2003 Rotary Club, Corona

4 Lake Arrowhead Teaching Seminar for the local community (Depression) patients; 1 session/year; 3 hours/year Harvard Medical School Instructor, Introduction to Clinical Medicine for second year Harvard Medical School students students/section; 2 sections/year; 6 hours/year Faculty and Medical House Staff Teaching Conference 2002 (Somatoform Disorders) residents; 3 hours/month; 24 hours/year Faculty, Physical Medicine and Rehabilitation Teaching Conference 2002 (Character Disorders, Somatoform Disorders) 4-5 faculty; 2 hours/week; 4 hours/year Individual Supervision for PGY III residents 2002 Harvard Southshore Department of Psychiatry West Roxbury Division 1 resident every 2 months; 8 hours/day; 2088 hours/year Depression in the Terminally Ill 2004 Annual Postgraduate Convention Management of the Frequent Flyer: Somatoform Disorders 2002 Internal Medicine Conference Management of the Frequent Flyer: Somatoform Disorders 2002 Spinal Cord Injury Medicine Conference, Management of Patients with Character Disorders 2002 Spinal Cord Injury Medicine Conference,

5 Smoking Cessation Lecture Series 2001 Jerry L. Pettis Veterans Hospital Visual Hallucinations 2001 Psychiatry Grand Rounds Befriending the Depressed 1998 Ambulatory Care Update Invited Presentations Book Chapter Mufson M, Quijada SLJ. Panic: Origins, Insight, and Treatment. In: Warner B (ed.). California: Atlantic Books, Clinical Research GlaxoSmithKline: A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo- Controlled, Flexible Dose Study to Evaluate the Efficacy, Safety and Tolerability of Extended- Release Bupropion Hydrochloride (xxxmg-xxxmg once daily) in Elderly Subjects with Major Depressive Disorder GlaxoSmithKline: A Twelve-Week, Multi-Center, Randomized, Double-Blind, Double- Dummy, Parallel-Group, Active Controlled, Escalating Dose Study to Compare the Effects on Sexual Functioning of Bupropion Hydrochloride Extended-Release (WELLBUTRINÔSL, xxxxxxmg/day) and Extended-Release Venlafaxine (EFFEXOR XR, xx-xxxmg/day) in Subjects with Major Depressive Disorder Pfizer: A Phase 3, Randomized, 6-Month, Double-Blind Trial in Subjects with Bipolar Disorder to Evaluate the Continued Safety and Maintenance of Effect of XXX Plus a Mood Stabilizer (Vs. Placebo Plus a Mood Stabilizer) Following a Minimum of 2 Months of Response to Open-Label Treatment with Both Agents Sanofi Aventis: An Eight-Week, Double-Blind, Placebo-Controlled, Multicenter Study with XXX as Positive Control, Evaluating the Efficacy, Safety, Tolerability of a Fixed Dose of XX in Outpatients with MDD Novartis: An 8-Week, Randomized, Fixed-Dose, Placebo-Controlled, Parallel-Group, Multi- Center Study of the Efficacy, Safety and Tolerability of XXX xx and xx mg in the Treatment of Major Depressive Disorder (MDD)

6 GlaxoSmithKline: A 12 Week Flexible Dose Study of XXX, Placebo and Active Control in the Treatment of Social Anxiety Disorder (SocAD) Sanofi-Aventis: A Multi-Center, Double-Blind, Parallel Group, Fixed Dose, 4-Arm, Placebo and XXX Controlled 8-Week Efficacy Study of 2 Oral Doses of XXX in Adult Outpatients with Major Depressive Disorder Novartis: An 8 week, Randomized, Double-Blind, Fixed-Dosage, Placebo-Controlled Parallel Group, Multi-Center Study of the Safety, Efficacy, and Tolerability of XXX 25mg and 50mg in the Treatment of Major Depressive Disorder Followed by a 52 Week, Open-Label Extension Pfizer: A Sixteen-Week, Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Switching From Quetiapine to Ziprasidone in Subjects Diagnosed with Schizophrenia or Schizoaffective Disorder 2008 Pfizer: A Phase 3, Randomized, Double-Blind, Parallel Group, Controlled Fixed Dose Study of XXX and XXXX in Evaluating the Efficacy and Safety of XXX for the Treatment of Generalized Anxiety Disorder Pfizer: A Phase 3, 52-Week, Open-Label Safety Study of XXX in Subjects With Generalized Anxiety Disorder Wyeth: An Open-Label Study to Evaluate the Prevalence of Phenotypic Poor Metabolizers at CYP2D6 Among Venlafaxine-Treated Outpatients with Depression 2009